A Unique Immune-Related Gene Signature Represents Advanced Liver Fibrosis and Reveals Potential Therapeutic Targets

Pil-Soong Sung, Chang-Min Kim, Jin-Kyeoung Kim, Jung-Hoon Cha, Jin-Young Park, Yun-Suk Yu, Hee-Jung Wang, Jin-Kyeoung Kim, and Si-Hyun Bae

Abstract: Innate and adaptive immune responses are critically associated with the progression of fibrosis in chronic liver diseases. In this study, we aim to identify a unique immune-related gene signature representing advanced liver fibrosis and to reveal potential therapeutic targets. Seventy-seven snap-frozen liver tissues with various chronic liver diseases at different fibrosis stages (1: n = 12, 2: n = 12, 3: n = 25, 4: n = 28) were subjected to expression analyses. Gene expression analysis was performed using the nCounter PanCancer Immune Profiling Panel (NanoString Technologies, Seattle, WA, USA). Biological meta-analysis was performed using the CBS Probe PINGS™ (CbsBiotechnology, Daejeon, Korea). Using non-tumor tissues from surgically resected specimens, we identified the immune-related, five-gene signature (CHIT1_FCER1G_OSM_VEGFA_ZAP70) that reliably differentiated patients with low- (F1 and F2) and high-grade fibrosis (F3 and F4; accuracy = 94.8%, specificity = 91.7%, sensitivity = 96.23%). The signature was independent of all pathological and clinical features and was independently associated with high-grade fibrosis using multivariate analysis. Among these genes, the expression of inflammation-associated FCER1G, OSM, VEGFA, and ZAP70 was lower in high-grade fibrosis than in low-grade fibrosis, whereas CHIT1 expression, which is associated with fibrogenic activity of macrophages, was higher in high-grade fibrosis. Meta-analysis revealed that STAT3, a potential druggable target, highly interacts with the five-gene signature. Overall, we identified an immune gene signature that reliably predicts advanced fibrosis in chronic liver disease. This signature revealed potential immune therapeutic targets to ameliorate liver fibrosis.

Keywords: gene signature; liver fibrosis; immune response; meta-analysis; macrophage

1. Introduction

Chronic liver diseases progress to liver cirrhosis, which affects 1–2% of people worldwide. There is a high death rate associated with cirrhosis, and patients die due to cirrhosis-related complications, such as gastrointestinal bleeding or hepatocellular carcinoma (HCC), which develop in one-third of cirrhosis cases [1]. Several approaches to reduce liver fibrosis are under investigation in order to eradicate hepatic decompensation, HCC, and other
fatal complications of cirrhosis [2], although no specific anti-fibrotic treatment is currently available. Recent strategies based on imaging and laboratory testing are not sufficiently predictive for identifying fibrotic progression and/or fibrogenic/carcinogenic activity in chronic liver diseases. Therefore, biomarkers with better reliability and sensitivity to predict liver fibrosis and patient outcomes are urgently required. Meanwhile, laboratory parameters, including the levels of serum albumin, bilirubin, and platelets, are within the normal range, and their smaller dynamic range is susceptible to non-specific variation, which makes them unreliable for predicting fibrosis progression or patient outcome [3].

A therapeutic target for anti-fibrosis may be revealed through expression analyses using liver biopsy specimens to distinguish between early and advanced liver fibrosis. A recently developed Nanostring nCounter technology makes it possible to perform gene expression analyses using minimal tissue samples [4]. The NanoString nCounter system is a nucleic acid hybridization platform that reliably detects the expression of up to 800 genes in a single assay [4]. Further biological meta-analyses make it possible to identify potential pathways and druggable targets after gene expression is measured [5]. These analyses may specifically focus on immune-related genes, which may be critically associated with liver fibrogenesis.

Intrahepatic macrophages are known to play critical roles in inflammation and fibrosis in chronic liver diseases [6]. Kupffer cells (KCs) are liver-resident, non-migratory macrophages capable of self-renewal and are derived from erythromyeloid progenitor cells in the fetal yolk sac [6,7]. They exist in the hepatic sinusoids and are different from the circulating monocyte-derived macrophages (MoMfs) originating from the bone marrow [8]. A recent study using livers from patients with nonalcoholic fatty liver disease showed that gut-derived LPS causes liver injury and inflammation by activating intrahepatic immune cells, such as KCs and MoMfs [9]. Activated macrophages then produce proinflammatory cytokines and amplify intrahepatic inflammation [10]. MoMfs differentiate into profibrogenic TREM2+CD9+ scar-associated macrophages and expand in the fibrotic liver when intrahepatic chronic inflammation is not stopped [11].

Overall, intrahepatic macrophages are critical for the initiation and progression of liver fibrosis. To identify potential therapeutic targets, in this study we perform a gene expression analysis using freshly frozen liver tissues at various stages of fibrosis using the nCounter PanCancer Immune Profiling Panel. Based on these analyses, we identified a macrophage-associated, novel immune-related gene signature associated with advanced fibrosis. Furthermore, we identified a potential druggable target derived from the gene signature and the resultant meta-analyses.

2. Methods

2.1. Patients and Tissue Samples

This study included 77 patients with histologically confirmed liver fibrosis. The inclusion criteria were as follows: (1) benign liver tissues with chronic liver diseases; (2) tissues obtained during hepatobiliary surgical procedures such as liver resection due to HCC. The exclusion criterion was the following: tissues that contain RNA with low purity or concentration not eligible to be analyzed by the nCounter PanCancer Immune Profiling Panel. Seventy-seven consecutive tissues were surgically obtained between 1995 and 2016 from the Ajou Medical Center. The retrospective protocol of this study was approved by the Institutional Review Board of the Ajou Medical Center (AJIRB-BMR-KSP-18-444) and The Catholic University of Korea (XC20EEDI0034). Fibrosis stage of the liver tissues were determined using the METAVIR scoring system.

2.2. RNA Extraction

RNA extraction was performed according to published methods [12]. Total RNA was extracted from non-tumor fibrosis tissues using a RNaseasy Mini Kit (QIAGEN, Hilden, Germany) with DNase I treatment (QIAGEN). RNA quality was verified by RNA integrity using a Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA). The total RNA
concentration was measured using a Nanodrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA).

2.3. Gene Expression Assay

Gene expression profiles were analyzed using nCounter MAX (NanoString Technologies, Seattle, WA, USA). The total reaction volume was 15 µL, containing 100 ng of RNA, reporter probes, and capture probes. The nCounter PanCancer Immune Profiling Panel (NanoString Technologies) was used for gene set profiling. Quality control and normalization of the raw data were performed using nSolver Analysis Software v4.0 (NanoString Technologies).

2.4. Gene Combination Analysis

Figure 1 shows a flow chart of the gene signature development and meta-analysis. Differentially expressed genes were defined as those that were significantly differentially expressed more than 2-fold between fibrosis stages 1 and 2 and fibrosis stages 3 and 4. Of the differentially expressed genes, the genes that were statistically significant in logistic regression analysis were included in the gene combination analysis. For the combination of differentially expressed genes, we identified the logistic regression coefficient of each gene and weighted gene expression with the corresponding coefficient value.

![Figure 1. Flow chart of gene signature development and meta-analysis.](image-url)
2.5. Cross-Validation as Pre-Validation of Candidate Gene Signatures

The candidate gene signatures (AUC > 0.9, accuracy > 90%, \( p < 0.05 \)) were pre-validated by k-fold cross-validation to identify the optimal gene combination. The patients were randomly separated by 2-folds (training set and test set) 300 times.

2.6. Biological Meta-Analysis

Biological meta-analysis was performed using the CBS Probe PINGS\textsuperscript{TM} (Reg. No. 2008-01-129-000568, CbsBioscience, Daejeon, Korea) that contains the following five modules: PPI, Path-Finder, Path-Linker, Path-Marker, and Path-Lister [5]. For gene signature validation, related signal transduction pathways were analyzed separately with the gene signature and differentially expressed genes of each fibrosis stage 3 and 4 patients. We selected the top 10 signal transduction pathways for the gene signature and each fibrosis stage 3 and 4 patients and identified highly interacting genes in these 10 pathways. We also compared the related gene signature pathways and all pathways related to fibrosis stage 3 and 4 patients. We compared the frequently interacting genes of the gene signature and all genes related to fibrosis stage 3 and 4 patients.

2.7. Statistical Analysis

The relationship between fibrosis stage and clinicopathologic variables was evaluated using the Chi-squared, Fisher’s exact, or Wilcoxon rank sum tests. Significant differences between fibrosis stages 1 and 2 and fibrosis stages 3 and 4 were evaluated using the Wilcoxon rank-sum test. Receiver operating characteristic curve analysis was used to determine the accuracy of threshold values for classifying fibrosis stages 1 and 2 and fibrosis stages 3 and 4. Gene signature independence was analyzed using logistic regression analysis between the gene signature and clinicopathologic variables. Statistical significance was set at \( p < 0.05 \) (two-tailed). All statistical analyses were performed in R version 3.4.3 (R Development Core Team, https://www.r-project.org/, accessed on 19 July 2021).

3. Results

3.1. Patient Characteristics

Baseline characteristics of the enrolled patients are presented in Table 1. This included patients with fibrosis stage 1 (\( n = 12 \)), stage 2 (\( n = 12 \)), stage 3 (\( n = 25 \)), and stage 4 (\( n = 28 \)). To identify the factors associated with advanced fibrosis (F3/4), we divided the enrolled patients into two groups: low- (F1/2, \( n = 24 \)) and high-grade fibrosis (F3/4, \( n = 53 \)). We defined low-grade and high-grade fibrosis according to the recent report describing significant worse liver-related outcome in patients with F3 and F4 fibrosis [13]. These benign fibrotic liver tissues were obtained from the non-tumor portion of the resected liver due to HCC. Therefore, the enrolled patients were predominantly male, and the principal etiology of chronic liver disease was chronic HBV infection (Table 1). In Korea, antiviral drugs for chronic HBV infection with normal liver enzymes are only reimbursed for patients with liver cirrhosis. Therefore, patients with advanced fibrosis were more likely to be treated with antiviral drugs. In most of the clinical and laboratory parameters, there were no statistically significant differences between the two groups, except for the platelet level, which was lower in patients with advanced liver fibrosis.

3.2. Expression Analysis-Derived Gene Signatures

We developed immune-related gene signatures in our patient tissue samples using a NanoString nCounter PanCancer Immune Profiling Panel. Nine candidate gene signatures were identified (Table 2). The rank of each gene signature was determined using the AUC of the receiver operating characteristic curves and positive and negative predictive values. The immune-related gene signature that was composed of CHIT1_FCER1G_OSM_VEGFA_ZAP70 was demonstrated to be the most accurate gene signature for predicting F3/4 fibrosis in chronic liver diseases (Table 2). The AUC of the receiver operating characteristic (ROC) curve of CHIT1_FCER1G_OSM_VEGFA_ZAP70 was 0.945 (95% CI, 0.894–0.996; Figure 2),
and the $p$-value by logistic regression analysis was $4.72 \times 10^{-8}$. The sensitivity and specificity of the gene signature were 96.23% and 91.67%, respectively. The positive and negative predictive values were 96.23% and 91.67%, respectively. For the other expression-analyses-derived gene signatures, we confirmed that these gene signatures can also accurately predict advanced fibrosis (Table 2). Figure 3 depicts the expression of each gene comprising the most accurate gene signature in F1/2 and F3/4 fibrosis. Chitotriosidase (CHIT1) expression (Figure 3A) was increased in F3/4 fibrosis and that of FCER1G, OSM, VEGFA, and ZAP70 (Figure 3B–E) was decreased. Supplementary Figure S1 describes the expression of each gene comprising the gene signature in each stage of liver fibrosis.

Table 1. Baseline characteristics of enrolled patients.

|                           | Fibrosis Stage 1–2 (N = 24) | Fibrosis Stage 3–4 (N = 53) | $p$ Value |
|---------------------------|------------------------------|------------------------------|-----------|
|                           | No. | %   | No. | %   |          |
| Sex                       |     |     |     |     |          |
| Male                      | 18  | 75.0| 43  | 81.1| 0.5556 *|
| Female                    | 6   | 25.0| 10  | 18.9|          |
| Mean age ($\pm$SD)        |     |     |     |     | 0.4474 *|
| Healtics B                |     |     |     |     | 0.0606 *|
| No                        | 8   | 33.3| 7   | 13.2|          |
| Yes                       | 16  | 66.7| 46  | 86.8|          |
| Hepatitis C               |     |     |     |     | 1.0000 *|
| No                        | 24  | 100.0| 51 | 96.2|          |
| Yes                       | 0   | 0.0 | 2   | 3.8 |          |
| Diabetes                  |     |     |     |     | 0.4761 #|
| No                        | 17  | 70.8| 43  | 81.1|          |
| Yes                       | 7   | 29.2| 10  | 18.9|          |
| BMI                       |     |     |     |     | 0.2546 #|
| $\leq$25 kg/m$^2$         | 18  | 75.0| 31  | 58.5|          |
| $>$25 kg/m$^2$            | 6   | 25.0| 22  | 41.5|          |
| ALT                       |     |     |     |     | 0.7843 #|
| $<$31 (F), $<$41 (M) IU/L | 16  | 66.7| 32  | 60.4|          |
| $\geq$31 (F), $\geq$41 (M) IU/L | 8 | 33.3 | 21 | 39.6 |          |
| AST                       |     |     |     |     | 0.2101 #|
| $<$31 (F), $<$37 (M) IU/L | 10  | 41.7| 13  | 24.5|          |
| $\geq$31 (F), $\geq$37 (M) IU/L | 14 | 58.3 | 40 | 75.5 |          |
| Platelets                 |     |     |     |     | 0.0144 #|
| $<$150 $\times$10$^9$/L   | 4   | 16.7| 26  | 49.1|          |
| $\geq$150 $\times$10$^9$/L | 20  | 83.3| 27  | 50.9|          |
| Antiviral treatment       |     |     |     |     | 0.0143 *|
| No                        | 24  | 100.0| 42 | 79.2|          |
| Yes                       | 0   | 0.0 | 11  | 20.8|          |
| Fibrosis                  |     |     |     |     | <0.0001 *|
| Stage 1                   | 12  | 50.0| 0   | 0.0 |          |
| Stage 2                   | 12  | 50.0| 0   | 0.0 |          |
| Stage 3                   | 0   | 0.0 | 25  | 47.2|          |
| Stage 4                   | 0   | 0.0 | 28  | 52.8|          |
| Etiology                  |     |     |     |     | 0.0543 *|
| HBV                       | 16  | 66.6| 46  | 86.8|          |
| HCV                       | 0   | 0.0 | 2   | 3.8 |          |
| Alcohol                   | 4   | 16.7| 3   | 5.6 |          |
| Others                    | 4   | 16.7| 2   | 3.8 |          |

SD, standard deviation; BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase. # Chi-squared test; * Fisher’s exact test; * Wilcoxon rank-sum test.
Table 2. Gene signatures derived from the expression analysis.

| Rank | Gene Signature | No. of Gene | Logistic Regression Continuous p-Value | ROC AUC | Threshold | Sensitivity | Specificity | Accuracy | PPV | NPV |
|------|----------------|-------------|----------------------------------------|---------|-----------|-------------|-------------|----------|------|-----|
| 1    | CHIT1_FCER1G_OSM_VEGFA_ZAP70 | 5           | 3.45 × 10⁻⁴ | 0.945 | -11.52614 | 96.23       | 91.67       | 94.81   | 96.23 | 91.67 |
| 2    | FCER1G_LTB_MME_OSM_VEGFA | 5           | 9.21 × 10⁻⁸ | 0.954 | -11.766822 | 94.34       | 91.67       | 93.51   | 96.15 | 88.00 |
| 3    | CD1B_CHIT1_FCER1G_OSM_VEGFA | 5           | 6.44 × 10⁻⁸ | 0.951 | -9.544123 | 94.34       | 91.67       | 93.51   | 96.15 | 88.00 |
| 4    | HLADRB3_OSM_VEGFA_ZAP70 | 4           | 4.05 × 10⁻⁴ | 0.951 | -11.382897 | 94.34       | 91.67       | 93.51   | 96.15 | 88.00 |
| 5    | CHIT1_FCER1G_MAF_OSM_VEGFA | 5           | 2.08 × 10⁻⁸ | 0.950 | -11.392033 | 94.34       | 91.67       | 93.51   | 96.15 | 88.00 |
| 6    | CHIT1_OSM_VEGFA_ZAP70 | 4           | 1.01 × 10⁻³ | 0.950 | -8.781110 | 94.34       | 91.67       | 93.51   | 96.15 | 88.00 |
| 7    | CD1B_OSM_TAPBP_VEGFA_ZAP70 | 5           | 7.31 × 10⁻⁸ | 0.943 | -13.930554 | 94.34       | 91.67       | 93.51   | 96.15 | 88.00 |
| 8    | CCL25_CHIT1_OSM_VEGFA_ZAP70 | 5           | 7.92 × 10⁻⁸ | 0.943 | -9.5199377 | 94.34       | 91.67       | 93.51   | 96.15 | 88.00 |
| 9    | CLEC4C_OSM_TAPBP_VEGFA_ZAP70 | 5           | 5.52 × 10⁻⁸ | 0.940 | -13.022690 | 94.34       | 91.67       | 93.51   | 96.15 | 88.00 |

ROC, receiver operating characteristic; AUC, area under curve; PPV, positive predictive value; NPV, negative predictive value; CHIT1, chitinase 1; FCER1G, Fc fragment of IgE receptor Ig; OSM, oncostatin M; VEGFA, vascular endothelial growth factor A; ZAP70, zeta chain of T-cell receptor associated protein kinase 70; LTb, lymphotixin beta; MME, membrane metalloendopeptidase; CD1B, CD1b molecule; HLADRB3, major histocompatibility complex, class II, DR beta 3; MAF, MAF bZIP transcription factor; TAPBP, TAP binding protein; CCL25, C-C motif chemokine ligand 25; CLEC4C, C-type lectin domain family 4 member C.

Figure 2. Clinical performance evaluation of the selected 5-gene signature. The clinical performance of the 5-gene signature was evaluated using receiver operating characteristic (ROC) analysis, cross-validation, and logistic regression analysis. (A) ROC analysis of 5-gene signature to the advanced fibrosis stage. (B) Clinical performance of the 5-gene signature in logistic regression analysis, cross-validation, and ROC analysis.
Figure 3. Expression of each gene comprising the gene signature in early stage versus late-stage liver fibrosis. Relative expressions of 5 genes in 24 patients with early-stage fibrosis and in 53 patients with late-stage fibrosis. ** \( p < 0.01 \). (A) CHIT1. (B) FCER1G. (C) OSM. (D) VEGFA. (E) ZAP70.

We further performed the expression analysis comparing F0 liver tissues (\( n = 17 \)) and fibrotic liver tissues (F1/2, \( n = 24 \), F3/4, \( n = 53 \)) of chronic liver diseases by the same technique. The data are presented in the Supplementary Figure S2. There was no significant difference between F0 and F1/2 or F0 and F3/4 fibrosis (Supplementary Figure S2).

Next, we divided our cohort into two subgroups: HBV-infected (\( n = 62 \)) and non-HBV patients (\( n = 15 \)) (Figure 4). First, we validated our gene signature (CHIT1_FCER1G_OSM_VEGFA_ZAP70) in the HBV-infected subgroup (Figure 4A). In the HBV-infected subgroup, the AUC of the ROC curve of CHIT1_FCER1G_OSM_VEGFA_ZAP70 was 0.955 (95% CI, 0.904–1.000), and the \( p \)-value by logistic regression analysis was \( 4.72 \times 10^{-6} \) (Figure 4A). In the non-HBV subgroup, the AUC of the ROC curve of CHIT1_FCER1G_OSM_VEGFA_ZAP70 was 0.929 (95% CI, 0.798–1.000), and the \( p \)-value by logistic regression analysis was \( 9.97 \times 10^{-1} \) (not significant) (Figure 4B).

Figure 4. Expression of each gene comprising the gene signature in each stage of liver fibrosis in the HBV ((A), \( n = 62 \)) and non-HBV ((B), \( n = 15 \)) subgroups.

3.3. Factors Associated with Pathological High-Grade Fibrosis

Next, univariate and multivariate analyses were performed with the gene signature and clinical parameters in order to identify the factors associated with pathological high-grade fibrosis (Table 3). Gene signature, HBV infection, and platelet count were significantly
associated with high-grade fibrosis in univariate analyses. These three statistically significant factors were selected as the parameters for multivariable analysis. Multivariate analysis revealed that only the gene signature was a statistically significant factor associated with high-grade fibrosis (odds ratio = 521.08, 95% CI: 31.21–8700.42, \( p < 0.001 \); Table 3).

**Table 3. Uni/Multi-variable logistic regression analysis.**

| Variable                                  | n  | Coefficient | Odds Ratio (95% CI) | se (Coefficient) | z       | p-Value     |
|-------------------------------------------|----|-------------|---------------------|------------------|---------|-------------|
| Gene signature (Low vs. High)             | 77 | 5.6366      | 280.50 (37.11–2120.26) | 1.0320           | 5.462   | 4.72 \times 10^{-8} |
| Age (\( \leq 55 \) years vs. >55 years)  | 77 | -0.2364     | 0.79 (0.28–2.23)    | 0.5296           | -0.446  | 0.655       |
| Sex (Male vs. Female)                     | 77 | -0.3600     | 0.70 (0.22–2.23)    | 0.5878           | -0.612  | 0.540       |
| BMI (\( \leq 25 \) kg/m^2 vs. >25 kg/m^2)| 77 | 1.1866      | 3.29 (1.03–10.51)   | 0.5934           | 2.005   | 4.50 \times 10^{-2} |
| Diabetes (absent vs. present)             | 77 | -0.5713     | 0.56 (0.18–1.73)    | 0.5700           | -1.002  | 0.316       |
| ALT (\( <31 \) F, <41 (M) IU/L vs. \( \geq 31 \) F, \( \geq 41 \) M IU/L) | 77 | 0.2719      | 1.31 (0.48–3.61)    | 0.5161           | 0.527   | 0.598       |
| AST (\( <31 \) F, <37 (M) IU/L vs. \( \geq 31 \) F, \( \geq 37 \) M IU/L) | 77 | 0.7875      | 2.20 (0.79–6.12)    | 0.5228           | 1.506   | 0.132       |
| Albumin (\( <4.0 \) g/dL vs. \( \geq 4.0 \) g/dL) | 77 | 0.3314      | 1.39 (0.49–3.96)    | 0.5335           | 0.621   | 0.534       |
| Platelets (\( <150 \) \times 10^9/L vs. \( \geq 150 \) \times 10^9/L) | 77 | -1.5717     | 0.21 (0.06–0.69)    | 0.6128           | -2.565  | 1.03 \times 10^{-2} |
| Antiviral treatment (absent vs. present)  | 77 | 18.0065     | 66885024.42 (0.00–Inf) | 1966.6495       | 0.009   | 0.678       |
| Simple steatosis (absent vs. present)     | 77 | -0.03577    | 0.98 (0.16–2.05)    | 0.6459           | -0.848  | 0.396       |

**Multivariable logistic regression**

| Variable                                  | n  | Coefficient | Odds Ratio (95% CI) | se (Coefficient) | z       | p-Value     |
|-------------------------------------------|----|-------------|---------------------|------------------|---------|-------------|
| Gene signature (Low vs. High)             | 77 | 6.2559      | 521.08 (31.21–8700.42) | 1.4364           | 4.355   | 1.33 \times 10^{-5} |
| HBV (absent vs. present)                  | 77 | 2.1565      | 8.64 (0.59–126.12)   | 1.3678           | 1.577   | 0.115       |
| Platelets (\( <150 \) \times 10^9/L vs. \( \geq 150 \) \times 10^9/L) | 77 | 0.5786      | 1.79 (0.13–24.46)    | 1.3359           | 0.433   | 0.665       |

3.4. Pathways and Genes Significantly Associated with the Gene Signature

Next, meta-analysis was performed to identify the pathways and genes significantly associated with the gene signature. The five-gene signature predictive of high-grade fibrosis was significantly associated with the Kyoto Encyclopedia of Genes and Genomes signal transduction pathways, including Kaposi’s sarcoma-associated herpesvirus infection, HPV infection, and EBV infection. The high interaction frequency genes associated with the gene signature were phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) and signal transducer and activator of transcription 3 (STAT3) (Table 4).

**Table 4. Meta-data analysis.**

| Pathway/Genes                                      |
|---------------------------------------------------|
| Kaposi sarcoma-associated herpesvirus infection   |
| Human papillomavirus infection                    |
| Epstein–Barr virus infection                      |

4. Discussion

In this study, we identified the immune gene signature that reliably predicts advanced fibrosis in chronic liver diseases using the nCounter PanCancer Immune Profiling Panel. This signature revealed potential immune therapeutic targets (STAT3) to ameliorate liver fibrosis.

Liver fibrosis is a common pathological consequence of most chronic liver diseases. Non-resolving liver injury is frequently accompanied by dysregulated wound healing and tissue repair, resulting in excessive deposition of the extracellular matrix. Intrahepatic macrophages play critical roles during this process, which can be reflected by the phenomenon that hepatic macrophage depletion alleviates liver fibrogenesis in mice [14,15]. In the early liver injury stage, KC CCL2 recruits proinflammatory and profibrogenic MoMFs, simultaneously producing proinflammatory cytokines to interact with hematopoietic stem cells to establish a profibrogenic niche [6,16,17]. A recent scRNA-seq study demonstrated
a previously unidentified macrophage type in the fibrotic niche of the human liver [11]. TREM2+CD9+ scar-associated macrophages are monocyte-derived cells in the fibrotic liver and terminally differentiated, showing a pro-fibrogenic phenotype [11,18]. Moreover, LC3-associated phagocytosis was reported in patients with cirrhosis [14,19]. LC3-associated phagocytosis is a non-canonical autophagy that triggers a phenotype change of MoMfs to an anti-inflammatory phenotype [14,19]. The pharmacological inhibition of LC3-associated phagocytosis in monocytes has demonstrated that the FcγRIIA-mediated activation of the anti-inflammatory pathway is caused by LC3-associated phagocytosis in cirrhosis patients [19]. Collectively, these recent reports suggest that the intrahepatic macrophage phenotype shifts from an inflammatory phenotype to an anti-inflammatory or pro-fibrogenic phenotype during the progression of liver fibrosis. In this study, we also demonstrated the upregulation of pro-inflammatory genes in F1/F2 fibrosis and subsequent decrease in the expression of these genes in F3/F4 fibrosis; however, the profibrogenic CHIT1 gene was upregulated in the advanced fibrosis stages. Interestingly, a recent report demonstrated that SPP1^{high} fibrogenic macrophages contribute significantly to lung fibrosis in idiopathic pulmonary fibrosis, and these macrophages express high levels of the CHIT1 gene [20].

In this study, using diseased liver tissues, we identified novel immune-associated gene signatures that can reliably predict advanced fibrosis. The signature is composed of five immune-related genes, namely CHIT1, FCER1G, OSM, VEGFA, and ZAP70. Among these genes, CHIT1 expression increased in F3/4 fibrosis, whereas that of the other genes decreased. CHIT1 is primarily secreted by activated macrophages under both normal and inflammatory conditions [21,22]. In HIV-infected smokers, CHIT1 expression in alveolar macrophages correlates with the expression of genes involved in innate immune responses [23]. In the liver, CHIT1 is primarily produced by activated KCs, which activate hepatic stellate cells to induce liver fibrosis [21,22]. FCER1G, also known as FcRγ, is constitutively expressed by monocytes and macrophages, and its expression can be induced in other myeloid cell types, such as neutrophils and eosinophils, when stimulated with IFN-γ, granulocyte colony-stimulating factor, IFN-α, and IL-12 [24]. OSM, VEGFA, and ZAP70 are also associated with the proinflammatory phenotype of macrophages.

Our meta-data analysis identified two genes associated with the gene signature for the advanced fibrosis: PIK3R1 and STAT3. PIK3R1 encodes the 85-kDa regulatory subunit of PI3K, p85α [25]. A human immunodeficiency was reported in patients with mutations in the PIK3R1 gene, suggesting that PI3K activity is critical in the activity of T and B cells [26]. Moreover, our group recently demonstrated that PI3K/Akt/mTOR signaling pathway in hepatic stellate cells contributes to the liver fibrogenesis [27]. We demonstrated that tenofovir disoproxil fumarate, an antiviral drug for HBV, directly ameliorates liver fibrosis in mice by downregulating the PI3K/Akt/mTOR signaling pathway, which results in the apoptosis of activated hepatic stellate cells [27]. Therefore, targeting PI3K pathway may be a possible therapeutic option for liver fibrosis.

STAT3 is a critical component of the JAK-STAT signaling pathway; however, deregulated STAT3 signaling results in inflammation, cancer, and fibrosis [28]. In this study, the meta-analyses using expression profiles revealed that PIK3R1 and STAT3 are highly interacting genes with the gene signature. STAT3 is a druggable target, and a recent study demonstrated that pharmacological inhibition of the STAT3 pathway ameliorates acute liver injury in vivo by controlling intrahepatic inflammatory macrophages [29]. Recent reports have indicated that STAT3 and its related cytokines have complex biological effects in liver fibrosis [30]. STAT3 pathway activation principally plays pro-inflammatory roles in liver fibrogenesis [30]. Recent clinical trials have demonstrated that liraglutide or semaglutide is an effective nonalcoholic steatohepatitis treatment [31,32]. A recent study demonstrated that liraglutide treatment decreases hepatic inflammation and injury in a nonalcoholic steatohepatitis animal model [33]. Specifically, liraglutide modulated primary KCs to M2-like activation via the STAT3 signaling pathway in wild mouse livers [34]. In palmitic-acid-treated macrophages, the amount of pSTAT3 decreased after treatment with
liraglutide, suggesting that STAT3-mediated proinflammatory signaling in macrophages is critical in nonalcoholic steatohepatitis livers [34].

5. Conclusions

In conclusion, using comprehensive expression analyses, we developed a novel immune-related gene signature that reliably predicts advanced fibrosis in chronic liver diseases. This signature revealed STAT3 as a potential therapeutic target for the treatment of liver fibrosis.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/biomedicines10010180/s1, Figure S1: Expression of each gene comprising the gene signature in each stage of liver fibrosis, Figure S2: Expression of each gene comprising the gene signature in F0, F1/2, and F3/4.

Author Contributions: P.-S.S.: study design, data collection, data analysis, data interpretation, manuscript writing, and manuscript approval. C.-M.K., J.-H.C.: data collection, data analysis, data interpretation, and manuscript writing. J.-H.C., J.-Y.P., Y.-S.Y., H.-J.W., J.-K.K.: data interpretation. S.-H.B.: data interpretation and manuscript approval. All authors have read and agreed to the published version of the manuscript.

Funding: This work was principally supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (2020R1A2C3011569). This work was partly supported by a Young Medical Scientist Research Grant through the Daewoong Foundation (DY20204P).

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of the Ajou University Medical Center (AJIRB-BMR-KSP-18-444) and The Catholic University of Korea (XC20EEDI0034).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Conflicts of Interest: The authors Chang-Min Kim, Jin-Young Park, and Yun-Suk Yu are employed by CbsBioscience. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors disclose no potential conflicts (financial, professional, or personal) of interest that are relevant to the manuscript.

Abbreviations

CHIT1: Chitotriosidase, HCC: hepatocellular carcinoma, KCs: Kupffer cells, MoMfs: monocyte-derived macrophages, ROC: receiver operating characteristic

References

1. Lesmana, C.R.A.; Raharjo, M.; Gani, R.A. Managing liver cirrhotic complications: Overview of esophageal and gastric varices. Clin. Mol. Hepatol. 2020, 26, 444–460. [CrossRef] [PubMed]
2. Odagiri, N.; Matsubara, T.; Sato-Matsubara, M.; Fujii, H.; Enomoto, M.; Kawada, N. Anti-fibrotic treatments for chronic liver diseases: The present and the future. Clin. Mol. Hepatol. 2020, 27, 413–424. [CrossRef] [PubMed]
3. Hoshida, Y.; Villanueva, A.; Sangiovanni, A.; Sole, M.; Hur, C.; Andersson, K.L.; Chung, R.T.; Gould, J.; Kojima, K.; Gupta, S.; et al. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013, 144, 1024–1030. [CrossRef] [PubMed]
4. Goytain, A.; Ng, T. NanoString nCounter Technology: High-Throughput RNA Validation. Methods Mol. Biol. 2020, 2079, 125–139. [CrossRef]
5. Park, I.J.; Yu, Y.S.; Mustafa, B.; Park, J.Y.; Seo, Y.B.; Kim, G.D.; Kim, J.; Kim, C.M.; Noh, H.D.; Hong, S.M.; et al. A Nine-Gene Signature for Predicting the Response to Preoperative Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer. Cancers 2020, 12, 800. [CrossRef]
6. Sung, P.S. Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma. Clin. Mol. Hepatol. 2021. [CrossRef]
7. Gomez Perdiguerio, E.; Klapproth, K.; Schulz, C.; Busch, K.; Azzoni, E.; Crozet, L.; Garner, H.; Trouillet, C.; de Bruijn, M.F.; Geissmann, F.; et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 2015, 518, 547–551. [CrossRef]
33. Ipsen, D.H.; Rolin, B.; Rakipovski, G.; Skovsted, G.F.; Madsen, A.; Kolstrup, S.; Schou-Pedersen, A.M.; Skat-Rordam, J.; Lykkesfeldt, J.; Tveden-Nyborg, P. Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis. *Basic Clin. Pharmacol. Toxicol.* **2018**, *123*, 704–713. [CrossRef]

34. Li, Z.; Feng, P.P.; Zhao, Z.B.; Zhu, W.; Gong, J.P.; Du, H.M. Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway. *Biochem. Biophys. Res. Commun.* **2019**, *510*, 20–26. [CrossRef] [PubMed]